Search alternatives:
progress decrease » progressive decrease (Expand Search), problems decreased (Expand Search)
changes decrease » largest decrease (Expand Search), change increases (Expand Search)
larger decrease » marked decrease (Expand Search)
progress decrease » progressive decrease (Expand Search), problems decreased (Expand Search)
changes decrease » largest decrease (Expand Search), change increases (Expand Search)
larger decrease » marked decrease (Expand Search)
-
8201
The framework diagram of this study.
Published 2025“…Mortality and postoperative complications did not change significantly (0.40% vs. 0.463%; 0.279% vs. 0.189%). …”
-
8202
Data Sheet 1_Global, regional, and national burden of ischemic heart disease attributed to non-optimal temperature, 1990–2021: an age-period-cohort analysis of the global burden of...
Published 2025“…Background<p>In recent years, non-optimal temperature has significantly impacted global health including ischemic heart disease (IHD).…”
-
8203
Figure 2 from mTORC1-Driven Protein Translation Correlates with Clinical Benefit of Capivasertib within a Genetically Preselected Cohort of <i>PIK3CA</i>-Altered Tumors
Published 2025“…Nodes are overlaid from the Cytoscape visualization, with fold-change shown by color. Node size increases as the <i>P</i>-value decreases. …”
-
8204
-
8205
-
8206
Image 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
-
8207
Table 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
-
8208
Image 4_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.tif
Published 2025“…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”
-
8209
Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co...
Published 2025“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
-
8210
Data Sheet 1_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.pdf
Published 2025“…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”
-
8211
Table 1_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.docx
Published 2025“…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”
-
8212
Image 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
-
8213
Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co...
Published 2025“…Data were extracted and analyzed for overall survival (OS), progression-free survival (PFS), response rates, and adverse events (AEs). …”
-
8214
Table 7_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
-
8215
Image 3_Hypothalamic FTO upregulates BDNF to promote GnRH expression through the PI3K/Akt pathway, leading to precocious puberty.tif
Published 2025“…</p>Results<p>Hypothalamic GnRH and FTO expression progressively increased whereas m6A methylation decreased during puberty. …”
-
8216
Table 1_FBR2 modulates ferroptosis via the SIRT3/p53 pathway to ameliorate pulmonary fibrosis.docx
Published 2025“…Background<p>Idiopathic Pulmonary Fibrosis (IPF), an interstitial lung disease of unknown etiology, remains incurable with current therapies, which fail to halt disease progression or restore lung function. However, Feibi Recipe No. 2 (FBR2), a clinically validated traditional Chinese medicine formula, exhibits potential as an IPF treatment.…”
-
8217
Table 8_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
-
8218
Table 2_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”
-
8219
Table 2_FBR2 modulates ferroptosis via the SIRT3/p53 pathway to ameliorate pulmonary fibrosis.xlsx
Published 2025“…Background<p>Idiopathic Pulmonary Fibrosis (IPF), an interstitial lung disease of unknown etiology, remains incurable with current therapies, which fail to halt disease progression or restore lung function. However, Feibi Recipe No. 2 (FBR2), a clinically validated traditional Chinese medicine formula, exhibits potential as an IPF treatment.…”
-
8220
Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…The primary outcomes were overall survival (OS) and progression-free survival (PFS), while the secondary outcomes included treatment responses and adverse events (AEs).…”